Pharmaceutical compound
| Combination of | |
|---|---|
| Aliskiren | Renin inhibitor |
| Amlodipine | Calcium channel blocker |
| Hydrochlorothiazide | Diuretic |
| Clinical data | |
| Trade names | Amturnide |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem CID | |
| KEGG | |
| Chemical and physical data | |
| Formula | C57H86Cl2N8O15S2 |
| Molar mass | 1258.38 g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Aliskiren/amlodipine/hydrochlorothiazide, sold under the brand name Amturnide, is a fixed-dose combination medication that is used to treat high blood pressure. It contains aliskiren, a renin inhibitor; amlodipine, as the besylate, a calcium channel blocker; and hydrochlorothiazide, a thiazide diuretic. It is taken by mouth.
It was approved for medical use in the United States in December 2010. Amturnide was withdrawn by Novartis from the US market in 2017.
References
- ^ "Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010". DailyMed. 10 November 2016. Retrieved 6 February 2022.
- Neutel JM, Smith DH (October 2013). "Hypertension management: rationale for triple therapy based on mechanisms of action". Cardiovascular Therapeutics. 31 (5): 251–8. doi:10.1111/1755-5922.12015. PMID 23121769.
- "Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010". DailyMed. Retrieved 5 July 2024.
- "Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045". U.S. Food and Drug Administration (FDA). 15 August 2011. Retrieved 27 August 2020.
- Lay summary in: "Center for Drug Evaluation and Research: Application Number: 200045Orig1s000: Summary review" (PDF). Food and Drug Administration.
- "Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications". Federal Register. 21 June 2017. Retrieved 6 February 2022.
External links
- "FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna)". U.S. Food and Drug Administration (FDA). 29 June 2021.
| Diuretics (C03) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sulfonamides (and etacrynic acid) |
| ||||||||
| Potassium-sparing (at CD) |
| ||||||||
| Osmotic diuretics (PT, DL) | |||||||||
| Vasopressin receptor inhibitors (DCT and CD) | |||||||||
| Other | |||||||||
| Combination products | |||||||||
| |||||||||
 | This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it. |